CardioComm receives FDA clearance for hand-held heart rhythm monitor.
M2 PHARMA-January 20, 2012-CardioComm receives FDA clearance for hand-held heart rhythm monitor(C)2012 M2 COMMUNICATIONS
20 January 2012 - CardioComm Solutions Inc (CVE:EKG), a US-based company specialising in the development of software and hardware related to personal heart arrhythmia monitoring systems, received the green light from the US Food and Drug Administration (FDA) to begin over-the-counter sales of its hand-held heart rhythm monitor known as the HeartCheck Pen Handheld ECG.
The FDA approval also covers CardioComm Solutions' GEMS (Global ECG Management System) Home software, which enables the HeartCheck Pen to be connected to a personal computer to upload data on the patient's heart rhythm to CardioComm Solutions' C4 medical call service telemedicine group for review by a physician.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 20, 2012|
|Previous Article:||J&J agrees to pay USD158m to settle Risperdal case in Texas.|
|Next Article:||NuPathe gets allowance of additional US patent application for migraine patch.|